Cognitive deficits are a core feature of schizophrenia, account for much of the impaired
functioning associated with the disorder and are not responsive to existing treatments. In this …

Clozapine is the gold standard for treatment-resistant schizophrenia. Serious and even life-
threatening adverse effects, mostly granulocytopenia, myocarditis, and constipation, are of …

Vitamin D deficiency is a frequent finding in schizophrenia and may contribute to
neurocognitive dysfunction, a core element of the disease. However, there is limited …

Background Patients with psychosis frequently use a variety of psychotropic medicines,
many of which have anticholinergic effects that can impair cognition. Therefore, this study …

Background Most medications used to treat psychotic disorders possess anticholinergic
properties. This may result in a considerable anticholinergic burden (ACB), which may have …

Background The prevention of relapse may be a key factor to diminish the cognitive
impairment of first-episode schizophrenia (FES) patients. We aimed to ascertain the effects …

Cognitive impairment has been associated with poor real-world functioning in patients with
Schizophrenia. Previous studies have shown that pharmacological treatment with …

Bipolar disorders (BD) are characterized by cognitive impairment during the euthymic
phase, to which treatments can contribute. The anticholinergic properties of medications, ie …

Aim The anticholinergic properties of medications are associated with poorer cognitive
performance in schizophrenia. Numerous scales have been developed to assess …

Drug-induced movement disorders (DIMDs) are associated with use of dopamine receptor
blocking agents (DRBAs), including antipsychotics. The most common forms are drug …